Trial
NCT01556347
Multi-Drug Desensitization Protocol for Heart Transplant Candidates
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Providence Health & Services
Collaborators
—
Condition
Heart Transplantation
Intervention
Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-06-15